Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Open Medicine

formerly Central European Journal of Medicine

Editor-in-Chief: Darzynkiewicz, Zbigniew


IMPACT FACTOR 2018: 1.221

CiteScore 2018: 1.01

SCImago Journal Rank (SJR) 2018: 0.329
Source Normalized Impact per Paper (SNIP) 2018: 0.479

ICV 2018: 156.09

Open Access
Online
ISSN
2391-5463
See all formats and pricing
More options …
Volume 5, Issue 5

Issues

Volume 10 (2015)

Hepatectomy for liver metastases from squamous cell laryngeal cancer. Is it worthy?

Alexander Julianov / Maya Gulubova
Published Online: 2010-08-20 | DOI: https://doi.org/10.2478/s11536-010-0035-4

Abstract

Patients with liver metastases from squamous cell head and neck cancer (SCHNC) are usually treated with chemotherapy and are not evaluated for eventual liver-directed treatment. However, the potential benefits from liver surgery for the patients with hepatic-only metastases from SCHNC generally remain undefined. We report a patient with late liver-only metastases from squamous cell glottic cancer treated with resection of the liver metastases followed by adjuvant platinum-based chemotherapy plus cetuximab. The patient died 25 months after resection of the hepatic metastases from widespread hepatic and pulmonary recurrence. The literature data as well as this case demonstrates the capability of liver surgery to prolong survival in patients with hepatic metastases from SCHNC.

Keywords: Head and neck cancer; Liver metastases; Liver resection

  • [1] Forastiere A.A., Metch B., Schuller D.E., Ensley J.F., Hutchins L.F., Triozzi P., et al., Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol, 1992, 10, 1245–1251 Google Scholar

  • [2] Jacobs C., Lyman G., Velez-Garcia E., Sridhar K.S., Knight W., Hochster H., et al., A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol, 1992, 10, 257–263 PubMedGoogle Scholar

  • [3] Clavel M., Vermorken J.B., Cognetti F., Cappelaere P., de Mulder P.H., Schornagel J.H., et al., Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol, 1994, 5, 521–526 Google Scholar

  • [4] Vermorken J.B., Mesia R., Rivera F., Remenar E., Kawecki A., Rottey S., et al., Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med, 2008, 359, 1116–1127 http://dx.doi.org/10.1056/NEJMoa0802656Web of ScienceCrossrefGoogle Scholar

  • [5] Choti M.A., Sitzmann J.V., Tiburi M.F., Sumethotimetha W., Rangsin R., Schulick R.D., et al., Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg, 2002, 235, 759–766 http://dx.doi.org/10.1097/00000658-200206000-00002CrossrefGoogle Scholar

  • [6] Grazi G.L., Cescon M., Pierangeli F., Ercolani G., Gardini A., Cavallarii A., et al., Highly aggressive policy of hepatic resections for neuroendocrine liver metastases. Hepatogastroenterology, 2000, 47, 481–486 Google Scholar

  • [7] Lendoire J., Moro M., Andriani O., Grondona J., Gil O., Raffin G., et al., Liver resection for non-colorectal, non-neuroendocrine metastases: analysis of a multicenter study from Argentina. HPB, 2007, 9, 435–439 http://dx.doi.org/10.1080/13651820701769701CrossrefGoogle Scholar

  • [8] Weitz J., Blumgart L.H., Fong Y., Jarnagin W.R., D’Angelica M., Harrison L.E., et al., Partial hepatectomy for metastases from noncolorectal, nonneuroendocrine carcinoma. Ann Surg, 2005, 241, 269–276 http://dx.doi.org/10.1097/01.sla.0000150244.72285.adCrossrefGoogle Scholar

  • [9] Ercolani G., Grazi G.L., Ravaioli M., Ramacciato G., Cescon M., Varotti G., et al., The role of liver resections for noncolorectal, nonneuroendocrine metastases: experience with 142 observed cases. Ann Surg Oncol, 2005, 12, 1–8 http://dx.doi.org/10.1245/ASO.2005.06.034CrossrefGoogle Scholar

  • [10] Elias D., Cavalcanti de Albuquerque A., Eggenspieler P., Eggenspieler P., Plaud B., Ducreux M., et al., Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients. J Am Coll Surg, 1998, 187, 487–493 http://dx.doi.org/10.1016/S1072-7515(98)00225-7CrossrefGoogle Scholar

  • [11] Adam R., Chiche L., Aloia T., Elias D., Salmon R., Rivoire M., et al., Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1452 patients and development of a prognostic model. Ann Surg, 2006, 244, 524–535 http://dx.doi.org/10.1097/01.sla.0000246847.02058.1bCrossrefGoogle Scholar

  • [12] Pawlik T.M., Gleisner A.L., Bauer T.W., Adams R.B., Reddy S.K., Clary B.M., et al., Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis. Ann Surg Oncol, 2007, 14, 2807–2816 http://dx.doi.org/10.1245/s10434-007-9467-8CrossrefGoogle Scholar

About the article

Published Online: 2010-08-20

Published in Print: 2010-10-01


Citation Information: Open Medicine, Volume 5, Issue 5, Pages 535–537, ISSN (Online) 2391-5463, DOI: https://doi.org/10.2478/s11536-010-0035-4.

Export Citation

© 2010 Versita Warsaw. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. BY-NC-ND 3.0

Comments (0)

Please log in or register to comment.
Log in